Arcadia Biosciences (RKDA) Total Non-Current Liabilities (2014 - 2025)

Arcadia Biosciences has reported Total Non-Current Liabilities for 12 years, with the latest figure at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 54.55% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (down 54.55% YoY), and the FY2025 full-year result was $2.4 million, down 54.55% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $2.4 million, down from $3.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $26.0 million in Q2 2021, with the low at $2.4 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $8.0 million across 5 years, with a median of $6.0 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 75.98% — and 2023, when it surged 79.78%.
• Arcadia Biosciences' Total Non-Current Liabilities stood at $10.7 million in 2021, then tumbled by 43.47% to $6.0 million in 2022, then declined by 16.94% to $5.0 million in 2023, then grew by 5.84% to $5.3 million in 2024, then tumbled by 54.55% to $2.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $2.4 million (Q4 2025), $3.1 million (Q3 2025), and $3.3 million (Q2 2025), per Business Quant data.